Fluoroquinolone-Associated Disability (FQAD)

Definition and regulatory framing

FQAD is defined not by validated diagnostic criteria but by the FDA's regulatory characterization: fluoroquinolones can cause "disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient." The distinguishing feature is the co-occurrence of adverse reactions across two or more body systems (musculoskeletal, peripheral nerve, CNS), often disabling, often persistent (at least 30 days, frequently months to years), sometimes after only a single dose or emerging months after therapy ends. There is currently no formally validated diagnostic criterion or biomarker.

The European Medicines Agency reached parallel conclusions in 2018 to 2019, restricting use in mild or self-limiting infections, adding heart-valve regurgitation warnings, and suspending marketing for several older quinolones. Regulatory harmonization remains incomplete; labels in Australia, New Zealand, Canada, and Japan do not uniformly carry FQAD-specific warnings.

Clinical features and symptom domains

The core triad emphasized by the label comprises tendinopathy and tendon rupture, peripheral neuropathy, and CNS effects. Tendinopathy most often involves the Achilles tendon but also the rotator cuff, hand, and biceps, and can be bilateral. Peripheral neuropathy is typically a sensory or sensorimotor axonal polyneuropathy (paresthesias, hypoesthesias, dysesthesias, weakness) that can begin within 24 hours and may be irreversible. CNS and neuropsychiatric manifestations include headache, dizziness, insomnia, confusion, hallucinations, anxiety, depression, psychosis, seizures, and suicidal ideation. Beyond the triad, the label recognizes aortic aneurysm and dissection, hypoglycemia (occasionally severe), QT prolongation, hepatotoxicity, and myasthenia gravis exacerbation.

Patients described as having FQAD commonly report a chronic syndrome of fatigue, concentration difficulty ("brain fog"), neuropathies, and tendinopathies persisting for years after exposure. In the WHO VigiBase analysis of 5,355 disabling musculoskeletal reports, onset was within 1 to 7 days in 61.5% of cases with data, yet duration exceeded 30 days in 65.3%. Most reports involved patients aged 18 to 64 (62.7%), with female predominance (61.8%); the most implicated agents were levofloxacin (50.0%) and ciprofloxacin (38.4%). This temporal signature, rapid onset but prolonged and sometimes progressive course despite discontinuation, is a hallmark distinguishing FQAD from most drug reactions.

Quantified risk and risk factors

The strongest and most modifiable risk factor is concomitant corticosteroid use, which raises the adjusted incidence rate ratio for Achilles rupture to 19.36 and, in patients 60 and older, produces an excess of roughly 19.6 tendon ruptures per 10,000. Other established risk factors are age over 60 (Achilles tendinitis OR 8.3 vs 1.6 in younger patients), renal impairment, organ transplantation (relative risk about 8 for tendon injury in lung transplant recipients on ciprofloxacin), male sex, strenuous physical activity, pre-existing tendon disease or rheumatoid arthritis, and, for aortic events, hypertension, atherosclerosis, Marfan and Ehlers-Danlos syndromes. Risk of neuropathy rises about 3% per additional day of exposure and persists up to 180 days after use. Notably, a large 2025 German population-based cohort found substantial relative risks of life-threatening events (aortic events, arrhythmia, hepatotoxicity, all-cause mortality) even in young adults 39 and under, with young women showing about 80% increased mortality hazard versus active comparators, challenging the assumption that risk is confined to the elderly.

Proposed pathophysiology

The pathogenesis is multifactorial and best conceptualized as a network of self-amplifying pathways, a framework that may explain why symptoms persist long after the drug is cleared:

Metal-ion chelation

Fluoroquinolones are potent chelators of magnesium, iron, zinc, copper, and manganese. Iron chelation inhibits alpha-ketoglutarate-dependent dioxygenases including collagen prolyl 4-hydroxylase (impairing collagen maturation) and histone/DNA demethylases (producing potentially long-lasting epigenetic changes). Magnesium chelation reproduces the cartilage lesions of dietary magnesium deficiency.

Mitochondrial toxicity and oxidative stress

A 2025 chemical-proteomics study identified selective downregulation of electron-transport-chain complexes I and IV within 3 hours, mediated by off-target binding to AIFM1 and IDH2. Ciprofloxacin also inhibits mitochondrial topoisomerase 2-beta, depleting mitochondrial DNA. Fluoroquinolones raise reactive oxygen species and deplete glutathione, with greater susceptibility in cells with reduced antioxidant capacity.

Collagen and extracellular-matrix disruption

Upregulation of MMP-2/MMP-9 with reduced TIMPs and lysyl oxidase degrades type I collagen in tendon and aortic wall; reduced beta-1-integrin signaling may trigger tenocyte anoikis. The aortic wall shares collagen I/III with tendon, linking the two toxicities mechanistically.

Neuronal targets

GABA-A receptor antagonism (governed by the C-7 piperazinyl substituent) underlies seizure risk, potentiated by certain NSAIDs; nicotinic acetylcholine receptor inhibition may explain myasthenia exacerbation. These mechanisms also underlie the neuropsychiatric spectrum from insomnia and anxiety to psychosis and suicidal ideation.

Dysglycemia

Hypoglycemia arises from K-ATP channel blockade in beta-cells (sulfonylurea-like insulin secretion) plus CYP2C9 interactions with sulfonylureas; moxifloxacin carries the highest dysglycemia risk.

Reversibility, prevention, and management

Reversibility is variable and often incomplete. In VigiBase, the reaction abated after drug withdrawal in only about 25% of cases with data (subject to reporting bias favoring poor outcomes). A distinguishing feature is delayed and progressive injury despite discontinuation, attributed to mitochondrial and cytotoxic effects. By contrast, in a tuberculosis cohort, 73.5% of fluoroquinolone-associated tendinopathy recovered with conservative measures.

Prevention rests on antimicrobial stewardship: reserving fluoroquinolones for patients without alternatives in uncomplicated UTI, acute sinusitis, and acute bronchitis exacerbation, and avoiding them, especially with concomitant corticosteroids, in older, renally impaired, or transplant patients and in those at aortic risk. The 2025 IDSA complicated-UTI guideline reinforces stewardship-driven reduction of fluoroquinolone use given both resistance and serious toxicity.

No evidence-based treatment protocol exists for established FQAD; management is supportive and largely empirical. Immediate steps are to discontinue the fluoroquinolone at the first sign of any serious reaction, switch to a non-quinolone antimicrobial, rest the affected tendon, and manage symptoms (analgesia, physical therapy; gabapentin, pregabalin, or duloxetine for neuropathic pain, though no FQ-specific trials exist). For clinicians evaluating new psychiatric symptoms after a fluoroquinolone course, the exposure history is a crucial and often overlooked part of the differential.

References

1. Michalak K, Sobolewska-Włodarczyk A, Włodarczyk M, et al. Treatment of the fluoroquinolone-associated disability: the pathobiochemical implications. Oxidative Medicine and Cellular Longevity. 2017;2017:8023935. doi.org/10.1155/2017/8023935
2. Huruba M, Farcas A, Leucuta DC, et al. A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders. Scientific Reports. 2021;11(1):14375. doi.org/10.1038/s41598-021-93763-y
3. Morales D, Pacurariu A, Slattery J, et al. Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy. JAMA Neurology. 2019;76(7):827-833. doi.org/10.1001/jamaneurol.2019.0887
4. Bangert MK, Hasbun R. Neurological and psychiatric adverse effects of antimicrobials. CNS Drugs. 2019;33(8):727-753. doi.org/10.1007/s40263-019-00649-9
5. Yu X, Jiang DS, Wang J, et al. Fluoroquinolone use and the risk of collagen-associated adverse events: a systematic review and meta-analysis. Drug Safety. 2019;42(9):1025-1033. doi.org/10.1007/s40264-019-00828-z
6. Wise BL, Peloquin C, Choi H, Lane NE, Zhang Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. The American Journal of Medicine. 2012;125(12):1228.e23-1228.e28. doi.org/10.1016/j.amjmed.2012.05.027
7. Persson R, Jick S. Clinical implications of the association between fluoroquinolones and tendon rupture: the magnitude of the effect with and without corticosteroids. British Journal of Clinical Pharmacology. 2019;85(5):949-959. doi.org/10.1111/bcp.13879
8. Morales DR, Slattery J, Pacurariu A, et al. Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone/corticosteroid therapy: population-based nested case-control study. Clinical Drug Investigation. 2019;39(2):205-213. doi.org/10.1007/s40261-018-0729-y
9. Wee I, Chin B, Syn N, et al. The association between fluoroquinolones and aortic dissection and aortic aneurysms: a systematic review and meta-analysis. Scientific Reports. 2021;11(1):11073. doi.org/10.1038/s41598-021-90692-8
10. Wicherski J, Peltner J, Becker C, et al. High risk for life-threatening adverse events of fluoroquinolones in young adults: a large German population-based cohort study. BMC Medicine. 2025;23(1):76. doi.org/10.1186/s12916-025-03919-0
11. Bove C, Baldock RA, Champigneulle O, Martin L, Bennett CL. Fluoroquinolones: old drugs, putative new toxicities. Expert Opinion on Drug Safety. 2022;21(11):1365-1378. doi.org/10.1080/14740338.2022.2147924
12. Tran PT, Antonelli PJ, Hincapie-Castillo JM, Winterstein AG. Association of US Food and Drug Administration removal of indications for use of oral quinolones with prescribing trends. JAMA Internal Medicine. 2021;181(6):808-816. doi.org/10.1001/jamainternmed.2021.1154
13. Getaneh B, Kerler J, Ganzorig M, et al. Fluoroquinolone-associated disability: a rodent model reveals transient neuropsychiatric and persistent gastrointestinal effects of low-dose ciprofloxacin. Pharmaceuticals. 2025;18(9):1277. doi.org/10.3390/ph18091277